Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Harvard Bioscience (HBIO) Enterprise Value (2016 - 2025)

Historic Enterprise Value for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to -$6.8 million.

  • Harvard Bioscience's Enterprise Value fell 4920.11% to -$6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.8 million, marking a year-over-year decrease of 4920.11%. This contributed to the annual value of -$4.1 million for FY2024, which is 408.59% up from last year.
  • According to the latest figures from Q3 2025, Harvard Bioscience's Enterprise Value is -$6.8 million, which was down 4920.11% from -$7.4 million recorded in Q2 2025.
  • Over the past 5 years, Harvard Bioscience's Enterprise Value peaked at -$3.8 million during Q1 2023, and registered a low of -$7.8 million during Q4 2021.
  • In the last 5 years, Harvard Bioscience's Enterprise Value had a median value of -$5.1 million in 2022 and averaged -$5.2 million.
  • As far as peak fluctuations go, Harvard Bioscience's Enterprise Value crashed by 13723.85% in 2021, and later surged by 4236.03% in 2022.
  • Quarter analysis of 5 years shows Harvard Bioscience's Enterprise Value stood at -$7.8 million in 2021, then skyrocketed by 42.36% to -$4.5 million in 2022, then increased by 4.99% to -$4.3 million in 2023, then increased by 4.09% to -$4.1 million in 2024, then tumbled by 65.94% to -$6.8 million in 2025.
  • Its Enterprise Value stands at -$6.8 million for Q3 2025, versus -$7.4 million for Q2 2025 and -$5.5 million for Q1 2025.